FI106984B - Testmetod och reagensförpackning avsedd för den - Google Patents
Testmetod och reagensförpackning avsedd för den Download PDFInfo
- Publication number
- FI106984B FI106984B FI932912A FI932912A FI106984B FI 106984 B FI106984 B FI 106984B FI 932912 A FI932912 A FI 932912A FI 932912 A FI932912 A FI 932912A FI 106984 B FI106984 B FI 106984B
- Authority
- FI
- Finland
- Prior art keywords
- gold
- analyte
- membrane
- protein
- complex
- Prior art date
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 39
- 238000010998 test method Methods 0.000 title 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 94
- 239000010931 gold Substances 0.000 claims abstract description 75
- 229910052737 gold Inorganic materials 0.000 claims abstract description 75
- 239000012491 analyte Substances 0.000 claims abstract description 73
- 239000002245 particle Substances 0.000 claims abstract description 44
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 42
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 40
- 102000004190 Enzymes Human genes 0.000 claims abstract description 22
- 108090000790 Enzymes Proteins 0.000 claims abstract description 22
- 239000007790 solid phase Substances 0.000 claims abstract description 13
- 239000012528 membrane Substances 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 44
- 230000027455 binding Effects 0.000 claims description 31
- 230000009870 specific binding Effects 0.000 claims description 18
- 239000000725 suspension Substances 0.000 claims description 17
- 239000007787 solid Substances 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 239000002250 absorbent Substances 0.000 claims description 7
- 230000002745 absorbent Effects 0.000 claims description 7
- 239000011148 porous material Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- 239000012911 assay medium Substances 0.000 claims description 4
- 238000009792 diffusion process Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 238000012875 competitive assay Methods 0.000 claims description 2
- 230000003100 immobilizing effect Effects 0.000 claims description 2
- 238000000527 sonication Methods 0.000 claims description 2
- 241001122767 Theaceae Species 0.000 claims 1
- 238000004451 qualitative analysis Methods 0.000 claims 1
- 238000004445 quantitative analysis Methods 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 26
- 239000000084 colloidal system Substances 0.000 description 24
- 239000008279 sol Substances 0.000 description 24
- 238000003556 assay Methods 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000000463 material Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 229940098773 bovine serum albumin Drugs 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 10
- 239000000020 Nitrocellulose Substances 0.000 description 9
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 229920001220 nitrocellulos Polymers 0.000 description 9
- 229940079938 nitrocellulose Drugs 0.000 description 9
- 238000010186 staining Methods 0.000 description 8
- 239000003154 D dimer Substances 0.000 description 7
- 108091006905 Human Serum Albumin Proteins 0.000 description 7
- 102000008100 Human Serum Albumin Human genes 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000001493 electron microscopy Methods 0.000 description 7
- 108010052295 fibrin fragment D Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000012085 test solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 102100032752 C-reactive protein Human genes 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 229920000915 polyvinyl chloride Polymers 0.000 description 5
- 239000004800 polyvinyl chloride Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090001008 Avidin Proteins 0.000 description 3
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Natural products CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000208 fibrin degradation product Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000123 paper Substances 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000002343 gold Chemical class 0.000 description 2
- ZBKIUFWVEIBQRT-UHFFFAOYSA-N gold(1+) Chemical compound [Au+] ZBKIUFWVEIBQRT-UHFFFAOYSA-N 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 101710083889 Alpha-fetoprotein Proteins 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- OXDZADMCOWPSOC-UHFFFAOYSA-N Argiprestocin Chemical compound N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 OXDZADMCOWPSOC-UHFFFAOYSA-N 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 102000014702 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 102100023981 Lamina-associated polypeptide 2, isoform alpha Human genes 0.000 description 1
- 101710163560 Lamina-associated polypeptide 2, isoform alpha Proteins 0.000 description 1
- 101710189385 Lamina-associated polypeptide 2, isoforms beta/gamma Proteins 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000898 Thymopoietin Substances 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 101800003024 Vasotocin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010042362 beta-Lipotropin Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- XJMXIWNOKIEIMX-UHFFFAOYSA-N bromo chloro 1h-indol-2-yl phosphate Chemical compound C1=CC=C2NC(OP(=O)(OBr)OCl)=CC2=C1 XJMXIWNOKIEIMX-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- -1 nucleoside triphosphates Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
- G01N33/553—Metal or metal coated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Inorganic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Claims (14)
1. Förfarande för kvalitativ eller kvantitativ be-stämning av en analyt i ett prov som undersöks, där en 5 märkt reagens som omfattar en guldsol bunden tili ett ämne som specifikt kan binda nämnda analyt eller tili en andra part som medverkar i den specifika bindningen, fäs att im-mobiliseras i bunden form pä en fast fas för att ge en in-dikation om förekomsten eller mängden av analyten i pro-10 vet, kännetecknat därav, att man använder en märkt reagens som omfattar ett superaggregerat komplex av nämnda ämne eller dess andra part som medverkar i den specifika bindningen och ett guldsol, där minst 75 vikt-% av guldsolets guldpartiklar har en medeldiameter under 20 15 nanometer.
2. Förfarande enligt patentkrav 1, kännetecknat därav, att nämnda prov bringas i kontakt, i ett vattenhaltigt bestämningsmedium, med (i) en analog till analyten eller med en specifik bindningspart för 20 nämnda analyt som är immobiliserad pä en fast bärare och (ii) med en märkt reagens, som omfattar det superaggrege-rade komplexet i patentkrav 1, med vilken en bestämd mängd av nämnda märkta reagens fäs att immobiliseras pä nämnda bärare, sä att den direkt eller indirekt ger upphov tili 25 en färgförändring som tyder pä en förekomst av eller upp- I . visar mängden av analyten. • · ♦ .1
.* 3. Förfarande enligt nägot av föregäende patent- • * * * ·* krav, kännetecknat därav, att minst 75 vikt-% ·*· ' » » » *·’ * av guldsolets guldpartiklar har en medeldiameter under 5 30 nanometer. • · ·
4. Förfarande enligt nägot av föregäende patent- • * · * : krav, kännetecknat därav, att man utför en • · · ' ; kompetitiv bestämning. * · · ♦ t • · 34 106984
5. Förfarande enligt nägot av patentkrav 1-3, kännetecknat därav, att man utför en skiktbe-stämning.
6. Förfarande enligt nägot av föregäende patent -5 krav, kännetecknat därav, att den fasta fasen är ett inert membran som lätt adsorberar protein och som innehäller porer som vätska kan tränga i genom.
7. Förfarande enligt patentkrav 1, kännetecknat därav, att det superaggregerade komplexet 10 är ett av tvä eller flera proteiner format hybridkomplex som innehäller en enzym som fär tili ständ en karakteris-tisk reaktion da den utsätts för ett substrat. därför.
8. Förfarande enligt patentkrav 1, kännetecknat därav, att det superaggregerade komplexet 15 är ett av tvä eller flera proteiner format hybridkomplex, och en färgförstärkning uppnäs genom att tillägga ett eller flera nya superaggregerade komplex som är kapabla att binda sig tili nämnda första hybridkomplex,
9. Reagensförpackning för kvalitativ och kvantita- 2. tiv bestämning av en analyt i. ett prov som undersöks, vil- ken omfattar (a) en fast fas pä vilken en märkt reagens fas att immobiliseras för att ge en indikation om förekom-: sten eller mängden analyt i provet och (b) en märkt rea- gens, kännetecknad därav, att den märkta rea- I < ... 2 5 gensen omfattar ett superaggregerat komplex av ett ämne i i t I . som specifikt kan bindas tili nämnda analyt eller tili • · a I) / dess andra part som medverkar i den specifika bindningen, • · · • ·’ och av en guldsol där minst 75 vikt-% av guldsolets guld- tn ·.· 1 partiklar har en medeldiameter under 20 nanometer.
10. Reagensförpackning enligt patentkrav 9, k ä n- : netecknad därav, att det superaggregerade kom- *’2; plexet dessutom innehäller en enzym som fär tili ständ en »»» ,1 . karakteristisk reaktion, och av att reagensförpackningen a « « a · · * 1 dessutom omfattar ett substrat för nämnda enzym. • · a · « • · < · · • · « 1 » · 2 • · 35 106984
11. Reagensförpackning enligt patentkrav 9, k ä n -netecknad av att den fasta fasen är en membran, en absorberande dyna är belägen pä nämnda membran, ett för vätska ogenomträngligt ark är beläget pä den sida av den 5 absorberande dynan som är bortät frän nämnda membran och ett för vätska ogenomträngligt ark med ett eller flera häl befinner sig pä den sida av membranen som är bortät frän den absorberande dynan, och den absorberande dynan förmär ästadkomma transversal diffusion av provet eller det märk-10 ta reagenset genom nämnda membran da det appliceras i ett av nämnda häl.
12. Förfarande för att preparera ett superaggrege-ratkomplex av protein och guldsol, där minst 75 vikt-% av guldsolets guldpartiklar har en medeldiameter under 20 15 nanometer, kännetecknat därav, att (i) proteinet och guldsolet blandas vid ett sädant pH-värde att det i proteinmolekylen förekommer minst tvä positivt laddade grupper; (ii) man samlar ihop de sälunda formade makrosko-20 piska aggregaten; (iii) man suspenderar de makroskopiska aggregaten pä nytt i en vätska, vars pH är neutralt, eventuellt med : ultraljudsbehandling, för att forma en suspension som in- nehäller stabila superaggregerade guld-protein-komplex. 25
13. Förfarande enligt patentkrav 12, kanne- « ( « I . t e c k n a t därav, att pH-värdet i skedet (i) är mellan • · · / 1 och 5. • 1 · • ·1
14. Superaggregerat komplex av ett protein och en ‘ guldsol, kännetecknat därav, att minst 75 30 vikt-% av guldpartiklarna har en medeldiameter under 20 : nanometer, och att det kan erhällas med förfarandet i pa- tentkrav 12 eller patentkrav 13. « • «
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9028038 | 1990-12-24 | ||
| GB909028038A GB9028038D0 (en) | 1990-12-24 | 1990-12-24 | Test method and reagent kit therefor |
| PCT/EP1991/002519 WO1992011537A1 (en) | 1990-12-24 | 1991-12-21 | Test method and reagent kit therefor |
| EP9102519 | 1991-12-21 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI932912L FI932912L (fi) | 1993-06-23 |
| FI932912A0 FI932912A0 (fi) | 1993-06-23 |
| FI106984B true FI106984B (sv) | 2001-05-15 |
Family
ID=10687595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI932912A FI106984B (sv) | 1990-12-24 | 1993-06-23 | Testmetod och reagensförpackning avsedd för den |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US5691207A (sv) |
| EP (1) | EP0564494B1 (sv) |
| JP (1) | JP3174573B2 (sv) |
| AT (1) | ATE115729T1 (sv) |
| AU (1) | AU648625B2 (sv) |
| CA (1) | CA2093415C (sv) |
| DE (1) | DE69106002T2 (sv) |
| DK (1) | DK0564494T3 (sv) |
| ES (1) | ES2065158T3 (sv) |
| FI (1) | FI106984B (sv) |
| GB (1) | GB9028038D0 (sv) |
| GR (1) | GR3014996T3 (sv) |
| IE (1) | IE66474B1 (sv) |
| NO (1) | NO311112B1 (sv) |
| WO (1) | WO1992011537A1 (sv) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU685443B2 (en) * | 1993-03-23 | 1998-01-22 | Smithkline Beecham Biologicals (Sa) | Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
| CA2105515A1 (en) * | 1993-09-03 | 1995-03-04 | Carlos A. Santizo Lescaille | Visual immunoassay method for the detection of ligands, based on the use of opaque plastic supports |
| JPH08311100A (ja) * | 1995-03-13 | 1996-11-26 | Terumo Corp | ヒト肺腺癌に関するモノクローナル抗体および抗原、及びそれを用いた免疫測定方法 |
| US5851777A (en) * | 1996-02-05 | 1998-12-22 | Dade Behring Inc. | Homogeneous sol-sol assay |
| EP0882224A4 (en) * | 1996-02-22 | 1999-06-09 | Dexall Biochemical Labs Inc | LIQUID PHASE IMMUNOASSAY WITH NON-CAPTURED SUBSTRATE |
| US6410692B2 (en) * | 1998-02-02 | 2002-06-25 | Novadx, Inc. | Removal of abundant interfering proteins from a liquid sample using a collapsible affinity matrix |
| US7297554B2 (en) * | 1998-11-18 | 2007-11-20 | Microdiagnostics, Inc. | Immunoassay system |
| FR2810739B1 (fr) * | 2000-06-26 | 2007-01-26 | Centre Nat Rech Scient | Immunodosage electrochimiques a l'aide de marqueurs metalliques colloidaux |
| DE10141691A1 (de) * | 2001-08-25 | 2003-03-13 | Friz Biochem Gmbh | Verdrängungsassay zur Detektion von Ligat-Ligand-Assoziationsereignissen |
| EP1520037A4 (en) * | 2002-02-27 | 2006-06-07 | Miragene Inc | CHEMICAL COMPOSITION WITH IMPROVED SUBSTRATE FOR IMMOBILIZATION OF PROTEIN ON RIGID SUPPORT |
| DE10211818B4 (de) * | 2002-03-16 | 2006-07-06 | peS Gesellschaft für medizinische Diagnose-Systeme mbH | Verfahren zur quantitativen Bestimmung mehrerer Analyten |
| US6824776B2 (en) * | 2003-04-16 | 2004-11-30 | The United States Of America As Represented By The Secretary Of The Navy | Silica mesoporous aerogels having three-dimensional nanoarchitecture with colloidal gold-protein superstructures nanoglued therein |
| DE602004012330T2 (de) * | 2004-04-29 | 2009-03-19 | Marc Ramael | Verfahren und kit zum nachweis von bestandteilen in einer probe |
| RU2413947C2 (ru) * | 2005-05-23 | 2011-03-10 | Фадиа Аб | Способы и устройства для двухэтапного латерального проточного анализа |
| ITUD20060177A1 (it) | 2006-07-14 | 2008-01-15 | Sire Analytical Systems Srl | Apparecchiatura integrata e metodo per la rilevazione di stati infiammatori presenti in un campione di sangue intero |
| US20100136517A1 (en) * | 2007-05-07 | 2010-06-03 | Massachusetts Institute Of Technology | Matrix stabilization of aggregation-based assays |
| US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
| US10527628B2 (en) | 2015-05-01 | 2020-01-07 | Diagnostear, Ltd. | Method for measuring tear constituents in a tear sample |
| US20190302028A1 (en) * | 2016-01-14 | 2019-10-03 | Diagnos Tear, Ltd. | Method for Measuring Tear Constituents in a Tear Sample |
| CN112578109B (zh) * | 2020-12-08 | 2022-10-11 | 广东海洋大学深圳研究院 | 定性定量检测试剂、制备方法及定性定量检测试剂盒 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3853987A (en) * | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| NL7807532A (nl) * | 1978-07-13 | 1980-01-15 | Akzo Nv | Metaal-immunotest. |
| GB2045431B (en) * | 1979-02-26 | 1983-04-20 | Technicon Instr | Immunoassay utilising two particulate reagents |
| US4434150A (en) * | 1981-10-19 | 1984-02-28 | Ortho Diagnostic Systems, Inc. | Immunological reagents employing polymeric backbone possessing reactive functional groups |
| US4880751A (en) * | 1986-10-31 | 1989-11-14 | Board Of Regents, The University Of Texas System | Immunoglobulin adsorption |
| US4859612A (en) * | 1987-10-07 | 1989-08-22 | Hygeia Sciences, Inc. | Metal sol capture immunoassay procedure, kit for use therewith and captured metal containing composite |
| DE3878167T2 (de) * | 1987-11-16 | 1993-05-27 | Janssen Pharmaceutica Nv | Auf ultrakleine kolloidale metallteilchen gegruendetes, allgemein anwendbares nachweissystem. |
| GB8800702D0 (en) * | 1988-01-13 | 1988-02-10 | Nycomed As | Test method & reagent kit therefor |
| AU7688191A (en) * | 1990-03-28 | 1991-10-21 | Board Of Regents, The University Of Texas System | Production of electrophoretically-uniform protein-colloidal gold complexes |
-
1990
- 1990-12-24 GB GB909028038A patent/GB9028038D0/en active Pending
-
1991
- 1991-12-21 US US08/039,426 patent/US5691207A/en not_active Expired - Lifetime
- 1991-12-21 WO PCT/EP1991/002519 patent/WO1992011537A1/en not_active Ceased
- 1991-12-21 JP JP50117592A patent/JP3174573B2/ja not_active Expired - Fee Related
- 1991-12-21 CA CA002093415A patent/CA2093415C/en not_active Expired - Fee Related
- 1991-12-21 AU AU90934/91A patent/AU648625B2/en not_active Ceased
- 1991-12-21 AT AT92901060T patent/ATE115729T1/de not_active IP Right Cessation
- 1991-12-21 ES ES92901060T patent/ES2065158T3/es not_active Expired - Lifetime
- 1991-12-21 DE DE69106002T patent/DE69106002T2/de not_active Expired - Fee Related
- 1991-12-21 DK DK92901060.1T patent/DK0564494T3/da active
- 1991-12-21 EP EP92901060A patent/EP0564494B1/en not_active Expired - Lifetime
- 1991-12-23 IE IE453691A patent/IE66474B1/en not_active IP Right Cessation
-
1993
- 1993-06-23 NO NO19932320A patent/NO311112B1/no unknown
- 1993-06-23 FI FI932912A patent/FI106984B/sv active
-
1995
- 1995-02-08 GR GR950400237T patent/GR3014996T3/el unknown
- 1995-06-07 US US08/482,751 patent/US5650333A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| NO311112B1 (no) | 2001-10-08 |
| AU9093491A (en) | 1992-07-22 |
| CA2093415C (en) | 2003-02-25 |
| NO932320L (no) | 1993-06-23 |
| ES2065158T3 (es) | 1995-02-01 |
| US5650333A (en) | 1997-07-22 |
| IE914536A1 (en) | 1992-07-01 |
| IE66474B1 (en) | 1995-12-27 |
| DE69106002D1 (de) | 1995-01-26 |
| DE69106002T2 (de) | 1995-05-11 |
| FI932912L (fi) | 1993-06-23 |
| US5691207A (en) | 1997-11-25 |
| EP0564494B1 (en) | 1994-12-14 |
| GR3014996T3 (en) | 1995-05-31 |
| GB9028038D0 (en) | 1991-02-13 |
| CA2093415A1 (en) | 1992-06-25 |
| FI932912A0 (fi) | 1993-06-23 |
| ATE115729T1 (de) | 1994-12-15 |
| WO1992011537A1 (en) | 1992-07-09 |
| AU648625B2 (en) | 1994-04-28 |
| DK0564494T3 (da) | 1995-03-06 |
| EP0564494A1 (en) | 1993-10-13 |
| JPH06503886A (ja) | 1994-04-28 |
| NO932320D0 (no) | 1993-06-23 |
| JP3174573B2 (ja) | 2001-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI92883C (sv) | Testförfarande och reagenskitt för detta | |
| FI106984B (sv) | Testmetod och reagensförpackning avsedd för den | |
| RU2025732C1 (ru) | Способ иммуноанализа аналита в водном образце | |
| JP2002521693A (ja) | 水溶性架橋結合体の製造方法 | |
| CA2164939A1 (en) | Rapid detection of analytes with receptors immobilized on soluble submicron particles | |
| CA2133967A1 (en) | Immobilization of specific binding assay reagents | |
| US5405752A (en) | Enzyme conjugate prepared with insoluble nonoparticle | |
| JP3484540B2 (ja) | 可溶性サブミクロン粒子上に固定化した抗体による抗原の無作為検出 | |
| FR2890173A1 (fr) | Dispositif de determination d'un analyte dans un echantillon liquide par un test sandwich et un test de competition | |
| US20160341723A1 (en) | Au nanoparticles encapsulated in nanocompoites and applications thereof in rapid detection of an analyte | |
| US20100173425A1 (en) | High Capacity Solid Phase | |
| JPH1068730A (ja) | イムノクロマト法用試験用具 | |
| CN117805359A (zh) | 一种肌红蛋白的均相检测试剂盒及其应用 | |
| CA2104596A1 (en) | Multi-test immunochemical reagent and method to use same | |
| EP0184701A2 (en) | A method for determining a ligand | |
| HK1001234B (en) | Test method and reagent kit therefor | |
| HK1001234A (en) | Test method and reagent kit therefor | |
| JPH0348766A (ja) | 免疫学的測定法 | |
| JP3727661B6 (ja) | シグナル発生酵素としてバナジウムブロモペルオキシダーゼを使った特異的結合リガンドの測定用の分析要素および方法 | |
| HK1001235B (en) | Test method and reagent kit therefor | |
| HK1001235A (en) | Test method and reagent kit therefor | |
| CN116859057A (zh) | 一种肌红蛋白的均相检测试剂盒及其应用 | |
| MXPA98004040A (en) | A particle resistant to storage, in particular a carrier for united reactions to carrier and the processes for the production of the |